Apyx Medical Corporation APYX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Apyx Medical Corporation in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Apyx Medical Corporation’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Apyx Medical Corporation's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Apyx Medical Corporation's cash & equivalents?
- Apyx Medical Corporation (APYX) reported cash & equivalents of $31.14M in Q1 2026.
- How has Apyx Medical Corporation's cash & equivalents changed year-over-year?
- Apyx Medical Corporation's cash & equivalents increased by 0.4% year-over-year, from $31.01M to $31.14M.
- What is the long-term trend for Apyx Medical Corporation's cash & equivalents?
- Over 5 years (2020 to 2025), Apyx Medical Corporation's cash & equivalents has grown at a -5.4% compound annual growth rate (CAGR), from $41.92M to $31.74M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.